Evidence map›Paper›PMID 25120824›Full record

ArticleInternational journal of clinical and experimental pathology2014

A case of blastic plasmacytoid dendritic cell neoplasm with ecchymotic lesions on the whole body.

Xiao-Bin Cui, Jing Jin, Xue-Lian Pang, Su Li, Chun-Xia Liu, Ting-Ting Li, Hao Peng, Shu-Mao Zhang, Li Li, Wei-Hua Liang and 2 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Dendritic Cell Leukemia: a Review.Current oncology reports · 2020
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Xiao-Bin CuiDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Jing JinDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Xue-Lian PangDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Su LiDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Chun-Xia LiuDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Ting-Ting LiDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Hao PengDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Shu-Mao ZhangDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Li LiDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine Shihezi, Xinjiang 832002, China.
Wei-Hua LiangDepartment of Pathology, The First Affiliated Hospital, Shihezi University School of Medicine Shihezi, Xinjiang 832002, China.
Yun-Zhao ChenDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Feng LiDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine Shihezi 832002, China.
Shihezi University · CNFirst Affiliated Hospital of Shihezi University Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) derived from plasmacytoid dendritic cell precursors is a very rare, and characterized by cutaneous and bone marrow involvement and leukemic spread. The neoplasm presents with an aggressive behavior, and the clinical findings include cytopenia, particularly thrombocytopenia. The tumor cells are negative for antigens of T- and B- cell lines. However, these cells express CD4, CD56 and CD123, which are markers of plasmacytoid dendritic cells, and negative for Epstein-Barr virus (EBV). From this point of view, a 71-year-old man who was initially found to have a cutaneous mass on his face and thorax was reported here, and initially was diagnosed as "eczema". The skin rashes then became aggravated on a trial of low dose topical corticosteroid for 2 months. According to skin biopsy, the tumor cells reveal an immature blastic appearance and positive for CD4 and CD56, negative for CD3, CD20, indicating a diagnosis of BPDCN. Here, we report the dismal course of a patient with BPDCN without accepting further therapy, and only survived 3 months.

Indexed as

AgedBiomarkers, TumorDendritic CellsEcchymosisHematologic NeoplasmsHumansMaleSkin NeoplasmsBiomarkers, TumorBlastic plasmacytoid dendritic cell neoplasmBPDCNneoplasm

Identifiers

PMID25120824
PMCPMC4129059
OpenAlexW1461775038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.